Your session is about to expire
← Back to Search
Lidocaine/Tetracaine Ointment vs Lidocaine/Prilocaine Cream for Photoaging
Phase 2 & 3
Recruiting
Led By Elika Hoss
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up after laser treatment, approximately 60 minutes
Awards & highlights
No Placebo-Only Group
Summary
This trial compares two topical treatments for numbing skin before a nonablative laser procedure.
Who is the study for?
This trial is for adults in good health with mild to moderate facial photoaging, who are undergoing a specific laser treatment. Women must use birth control if of childbearing potential. Excluded are those with certain skin conditions, severe diseases, recent use of isotretinoin or steroids, allergies to the anesthetics used, and pregnant or breastfeeding women.
What is being tested?
The study compares two topical anesthetics: lidocaine/tetracaine ointment without occlusion versus lidocaine/prilocaine cream with occlusion before nonablative laser procedures on the face. The goal is to see which one is more effective at numbing the skin.
What are the potential side effects?
Potential side effects may include reactions at the application site such as redness, swelling, itching or discomfort; rare systemic effects could be related to absorption like dizziness or irregular heart rate.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ after laser treatment, approximately 60 minutes
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~after laser treatment, approximately 60 minutes
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Self-reported pain after laser treatment
Secondary study objectives
Self-reported burning after laser treatment
Self-reported itching after laser treatment
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Active Control
Group I: 2.5 g of lidocaine 23% / tetracaine 7% ointmentActive Control1 Intervention
Patients undergoing 1927 nm fractional thulium fiber laser treatment of the face for photodamage as part of normal clinical care will have randomly assigned half of the face applied with 2.5 g of lidocaine 23% / tetracaine 7% ointment without occlusion for 60 minutes.
Group II: 7.5 g lidocaine 2.5%/ prilocaine 2.5% creamActive Control1 Intervention
Patients undergoing 1927 nm fractional thulium fiber laser treatment of the face for photodamage as part of normal clinical care will have randomly assigned half of the face applied with 7.5 g lidocaine 2.5%/ prilocaine 2.5% cream with occlusion for 60 minutes.
Find a Location
Who is running the clinical trial?
Mayo ClinicLead Sponsor
3,357 Previous Clinical Trials
3,062,383 Total Patients Enrolled
Elika HossPrincipal Investigator - Mayo Clinic
Mayo Clinic Arizona
University Of Arizona College Of Medicine (Medical School)
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a wound that hasn't fully healed or a skin condition in the area where the treatment will be given.You have allergies or sensitivities to any of the ingredients in the topical products being used in this study.You are currently receiving 1927nm fractional thulium laser treatment.
Research Study Groups:
This trial has the following groups:- Group 1: 2.5 g of lidocaine 23% / tetracaine 7% ointment
- Group 2: 7.5 g lidocaine 2.5%/ prilocaine 2.5% cream
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.